UC Davis Health Clinical Studies

A Study of Experimental INS1007 For Non-Cystic Fibrosis Bronchiectasis (damage to airways, making it difficult to clear mucus)

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

This is a clinical research study of an experimental drug called INS1007. “Experimental” means that the study drug is currently being tested in clinical research studies. We might not have all the information about it. INS1007 is not approved to treat non Cystic Fibrosis (CF) bronchiectasis by the Food and Drug Administration (FDA). It is undergoing clinical investigations to determine if INS1007 is safe and effective. INS1007 is taken as tablets and has been studied in animals and humans. Patients like you, with non CF bronchiectasis, may have problems with managing sputum movemen. You may also have worsening respiratory symptoms. INS1007 may help manage these issues. The purpose of this clinical research study is to evaluate the safety and effectiveness of INS1007 as a treatment for non-CF bronchiectasis. We also want to measure the concentration of INS1007 in the blood after treatment.

Drug study, Phase 2
Any, age 18 to 85 years old

Sigh Ventilation to Increase Ventilator-Free Days in Victims of Trauma at Risk for Acute Respiratory Distress Syndrome

The study team wants to know if adding a sigh-type of breath to a ventilator reduces chances of developing more serious lung problems.

When patients have breathing problems, some may need support from a machine that helps them breathe. This machine is called a mechanical ventilator. Most of the time the machine works by delivering the same amount of air each time the patient takes, or is given, a breath. This study plans to examine adding large breaths, like you take when you sigh or yawn. These will be given at a rate that is like the rate people normally sigh. The study team wants to know if adding this type of breath will reduce the chance of you developing more serious lung problems.

Other study
Any, age 18 to 89 years old

A Research Study to Test the Safety and Effectiveness of Experimental Treatment With Inhaled Nitric Oxide for Pulmonary Fibrosis

This study aims to find out if the study drug, nitric oxide, may help treat pulmonary fibrosis (PF).

This study aims to find out if the study drug, nitric oxide, may help treat pulmonary fibrosis (PF). It will be given through an investigational study device, the INOpulse. Inhaled nitric oxide is a drug approved by the FDA and Health Canada for the treatment of infants. These infants have difficulty breathing and have decreased oxygen in their blood, associated with pulmonary hypertension (PH). Inhaled nitric oxide and the INOpulse delivery device are investigational for the treatment of pulmonary fibrosis (PF). The combination is not currently an approved treatment.

Drug study, Phase 2
Any, age 18 to 80 years old

Experimental Combination of Afatinib With Pembrolizumab (two cancer drugs) for Squamous Cell Carcinoma of the Lung

An experimental drug combination treatment for Non-Small Cell Lung Cancer.

This study aims to find the best dose of the study drug, called afatinib. The dose will be used for this study and for future clinical studies. Different doses of afatinib, will be tested in combination with pembrolizumab. The study team wants to see which dose of afatinib is safer in subjects with non-small cell lung cancer (NSCLC). The study will test the safety and effectiveness of afatinib combined with pembrolizumab. Afatinib (trade name Gilotrif®) on its own has been approved by the U.S. Food and Drug Administration (FDA). It is used to treat squamous cell carcinoma of the lung. Pembrolizumab, is approved in the USA and some other countries. It is available by prescription to treat several different cancers, but may not be approved to treat your type of cancer. The study drug afatinib, is being supplied by another country and is being combined with pembrolizumab. The study drugs are considered experimental for this study.

Drug study, Phase 2
Any, age 18 years or older

Evaluation of a Medical Test for Management of the Flu in the Emergency Department

Knowing whether patients have this infection may help prevent the spread of the virus to other hospitalized patients.

We invite you to take part in a research study because your emergency healthcare provider suspects that you may have influenza. This is also known as “the flu” or a similar infection called “RSV.” Your doctor has already ordered a test to check whether you have the flu or RSV. Many people each year suffer from the flu and RSV. In this study, we want to provide doctors with a quick experimental test to determine if their patients have flu or RSV. We will see if this increases the use of antiviral medication, instead of antibiotics and what effect this has on the patient’s overall health. Knowing whether patients have this infection may help prevent the spread of the virus to other hospitalized patients.

Device study
Any, age 1 to 20 years old
Loading